SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix reported strong Q4 2025 financial results with $128.6 million…

CorMedix Inc. · 8-K filed Mar 5, 2026 at 07:48 ET

At the news

BULLISHIMPACT 8/10

8-K filed Mar 5, 2026 at 07:48 ET

CorMedix reported strong Q4 2025 financial results with $128.6 million in revenue, driven by DefenCath and the recent Melinta acquisition, and achieved full-year revenue of $311.7 million ($401.3 million pro forma). The company posted net income of $163.0 million and reiterated 2026 guidance of $300-$320 million in revenue and $100-$125 million in adjusted EBITDA, while announcing a $75 million share repurchase program.

  • Q4 2025 revenue was $128.6 million, up from $31.2 million in Q4 2024
  • Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million
  • Q4 2025 net income was $14.0 million; full-year net income was $163.0 million
  • Adjusted EBITDA for Q4 2025 was $77.2 million, up from $15.3 million in Q4 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access